The holidays officially begin this week — at least at Starbucks — when the coffee chain rolls out its annual seasonal cups.

CAMBRIDGE, MA / ACCESSWIRE / November 12, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked the number one large employer in ...

Leerink Partners analyst Mani Foroohar assigned a Sell rating on Moderna (MRNA – Research Report) on November 7 and set a price target of ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

Welcome to the Moderna third quarter 2024 conference call. [Operator instructions] Please be advised today's conference is ...

The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory syncytial virus vaccine raked in just $10 ...

Shares up nearly 5% to $54.22 in early trading Spikevax COVID vaccine sales reached $1.8 billion, beating expectations Moderna expects lower COVID vaccine sales this year compared to 2023 $10 ...

Thermory has announced the winners of its annual design awards, including an addition to Lisbon's Centro de Arte Moderna ...

Other vaccines (such as Moderna) were excluded from analyses. The final older (12-17 years) study cohort comprised 872,936 ...

Shares of Moderna Inc. MRNA shed 6.86% to $46.83 Friday, on what proved to be an all-around favorable trading session for the ...

Shares of Moderna Inc. MRNA slid 2.95% to $50.28 Thursday, on what proved to be an all-around mixed trading session for the ...

Merck and Moderna initiate Phase 3 trial of mRNA-4157 (V940) with Keytruda as adjuvant for NSCLC patients, marking progress in individualized cancer therapies. Vandana Singh Benzinga Bulls And ...